CRS-207

Term: CRS-207Definition: CRS-207 is an experimental immunotherapy treatment designed to stimulate the immune system to target and destroy cancer cells, particularly in mesothelioma patients affected by asbestos exposure.Phonetic Pronunciation: (C-R-S-two-oh-seven)Origin: The term CRS-207 is derived from its designation in clinical research. It is a product of Aduro Biotech, Inc., and the name reflects its position as the 207th compound in the company's research series. The "CRS" part of the name likely stands for "Cancer Research Series."Significance in Asbestos Context: CRS-207 is significant in the context of asbestos-related diseases because it offers a potential new treatment avenue for mesothelioma, a cancer strongly linked to asbestos exposure. This immunotherapy could improve outcomes for patients who have limited options due to the aggressive nature of the disease.Example Sentence: "After being diagnosed with mesothelioma due to asbestos exposure, the patient enrolled in a clinical trial for the immunotherapy treatment CRS-207 in hopes of extending their life expectancy."Related Terms: Immunotherapy, Mesothelioma, Asbestos Exposure, Cancer Treatment, Clinical TrialNotes: - CRS-207 is still under investigation and not yet approved for general use. - It is specifically designed for use in combination with other treatments. - Results from clinical trials are promising but more research is needed.